Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with vector biology, trial biomarkers and financing clauses is tough. Lexeo Therapeutics’ SEC disclosures are especially dense because each Form 10-K and 10-Q weaves together gene-therapy science, licensing terms with Cornell, and the cash runway needed to advance Friedreich ataxia and APOE4 Alzheimer’s trials. If you have ever asked, “How do I find Lexeo Therapeutics insider trading Form 4 transactions?” or “Where is the Lexeo Therapeutics quarterly earnings report 10-Q filing?”, you already know the challenge.
Stock Titan solves it. Our platform delivers AI-powered summaries that transform hundreds of pages into key takeaways—R&D spend, trial milestones, dilution risks. Get real-time alerts whenever a Lexeo Therapeutics 8-K material event is filed or when a scientist reports stock activity on a Form 4. The result: Lexeo Therapeutics SEC filings explained simply, without losing clinical nuance.
Use cases investors rely on every day:
- Track Lexeo Therapeutics Form 4 insider transactions real-time to gauge management confidence.
- Read a Lexeo Therapeutics annual report 10-K simplified to spot cash-burn trends and IP updates.
- Run a Lexeo Therapeutics earnings report filing analysis to compare quarter-over-quarter R&D progress.
- Review a Lexeo Therapeutics proxy statement executive compensation section in plain English.
Whether you’re understanding Lexeo Therapeutics SEC documents with AI for academic research or monitoring Lexeo Therapeutics executive stock transactions Form 4 before the next data release, Stock Titan gives you complete, continuously updated coverage—and the clarity you need to act decisively.
Balyasny Asset Management and related entities reported beneficial ownership of 8,345,651 shares of Lexeo Therapeutics common stock, representing approximately 9.99% of the outstanding shares based on the issuer's reported share count. The position includes 4,336,514 shares issuable upon exercise of warrants, and the filing states the warrants cannot be exercised to the extent they would cause the holders to beneficially own more than 9.99% (a 9.99% blocker).
The filing explains that the reported shares are held through an investment client (Atlas Diversified Master Fund, Ltd.) for which Balyasny serves as investment manager, and that the Reporting Persons have sole voting and dispositive power over the reported shares. The Reporting Persons certified the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
What is the current stock price of Lexeo Therapeutics (LXEO)?
What is the market cap of Lexeo Therapeutics (LXEO)?
